What is the current market size?

The Needle Based Biopsy Gun market size reached USD 1.2 billion in 2023, driven by rising cancer diagnostics and minimally invasive procedures.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advanced healthcare infrastructure and technological innovation.

What are the key drivers of market growth?

Key drivers include increasing oncology screening, demand for accurate diagnostics, and adoption of needle biopsy guns in outpatient settings.

What challenges does the market face?

Challenges include stringent regulatory compliance, high device costs, and risks of tissue sampling errors impacting adoption rates.

Which regions are leading the market?

North America and Europe lead the market due to established healthcare systems, while Asia-Pacific shows rapid growth from rising medical tourism.

Who are the top companies in the market?

Leading companies include Medtronic, Boston Scientific, and Cook Medical, focusing on R&D and strategic partnerships to enhance market share.

What future opportunities exist?

Opportunities lie in AI-integrated biopsy systems, expanding applications in non-oncology diagnostics, and emerging markets in Latin America.

How is technology impacting the market?

Technological advancements like real-time imaging and automated needle guidance are improving accuracy and reducing procedure time significantly.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA emphasize safety and efficacy, requiring rigorous testing, which ensures market credibility but delays product launches.

Needle Based Biopsy Gun Growth Trends & Strategic Outlook 2033

Needle Based Biopsy Gun by Application (Hospitals, Ambulatory Surgical Centers, Others), by Types (Vacuum-Assisted, Fine Needle, Core Needle), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1017 million

CAGR: 7.6%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1017 million

CAGR: 7.6%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Needle Based Biopsy Gun Market Overview

The Needle Based Biopsy Gun market refers to medical devices used for rapid, minimally invasive tissue sampling in diagnostic procedures, primarily in oncology, radiology, and urology. As a critical tool in early disease detection and treatment planning, its relevance in global healthcare is underscored by the rising demand for non-surgical diagnostic alternatives. The Needle Based Biopsy Gun market size is estimated at $1.2 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.5% through 2033. This growth outlook is driven by advancements in imaging technologies, increasing incidence of cancer, and the adoption of minimally invasive procedures. The market forecast projects robust industry expansion, supported by innovations in biopsy automation and regulatory approvals streamlining product adoption.

Loading chart…

Key forces shaping the Needle Based Biopsy Gun market include technological shifts toward automated biopsy systems and real-time imaging integration, enhancing procedural precision. Regulatory frameworks, particularly in the U.S. and EU, are tightening to ensure device safety, influencing product design and market entry strategies. Consumer behavior trends favor outpatient diagnostic settings, accelerating demand in ambulatory surgical centers. North America remains the largest region, leveraging advanced healthcare infrastructure and high R&D investments. Conversely, Asia-Pacific is the fastest-growing region, fueled by rising healthcare expenditure, expanding diagnostic facilities, and growing awareness of early disease detection. Strategic partnerships between device manufacturers and imaging technology firms are poised to redefine competitive dynamics over the forecast period.

Report Overview

Report Attribute	Details
Market size value in 2025	1.02 billion
Revenue forecast in 2033	1.77 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	C. R. Bard; Becton Dickinson and Company; Cook Group Incorporated; Leica Biosystems; Argon Medical Devices; B. Braun Melsungen; Cardinal Health; Olympus Corporation; Boston Scientific Corporation; FUJIFILM Holdings Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of cancer: The global increase in cancer diagnoses is directly elevating demand for minimally invasive diagnostic tools like the Needle Based Biopsy Gun market, which enables accurate tissue sampling with reduced patient trauma and recovery time.

Technological advancements in image-guided systems: Innovations such as real-time ultrasound integration and automated biopsy mechanisms are enhancing procedural precision, driving adoption in diagnostic imaging centers and hospitals.

Restraints2 items

High initial costs: Advanced biopsy guns require significant capital investment, limiting accessibility in low- and middle-income regions despite their long-term cost-efficiency in reducing complications.

Shortage of trained professionals: The need for skilled interventional radiologists or pathologists to operate these devices restricts market penetration, particularly in underserved areas.

Opportunities2 items

Expansion into emerging markets: Growing healthcare infrastructure in Asia-Pacific and Latin America, coupled with increasing cancer screening programs, presents a strong growth forecast for the Needle Based Biopsy Gun market size over the next decade.

Integration with AI-driven diagnostics: Combining biopsy guns with artificial intelligence for real-time tissue analysis could revolutionize early-stage cancer detection, creating a competitive edge for forward-thinking manufacturers.

Challenges2 items

Regulatory complexity: Varying FDA, CE, and ISO certification requirements across regions delay product launches and increase compliance costs, particularly for small-to-mid-sized manufacturers.

Competition from non-invasive alternatives: The rise of liquid biopsy technologies, though less precise, offers a non-invasive alternative that could divert budget allocation away from the Needle Based Biopsy Gun market in certain applications.

Market Segmentation

Loading chart…

Application segmentation in the Needle Based Biopsy Gun market delineates demand by medical specialty. The primary driver is oncology, where the device is critical for diagnosing solid tumors, accounting for 55% of the market value. Cardiology follows closely at 30%, leveraging the technology for vascular and cardiac tissue analysis. Remaining 15% encompasses dermatology, urology, and gastroenterology, where precision biopsies are essential for non-cancerous pathologies. This taxonomy underscores the market's reliance on oncology and cardiology, with growth potential in niche applications. The Needle Based Biopsy Gun segmentation by application highlights how procedural demand across specialties shapes market dynamics.

Types segmentation distinguishes the market by technical design. Core Needle Biopsy (CNB) dominates at 65%, offering larger tissue samples for histopathology, preferred in oncology. Fine Needle Aspiration (FNA) constitutes 35%, utilized for cytology sampling in thyroid and breast diagnostics. CNB's dominance reflects its role in complex diagnostics, while FNA's agility supports high-volume, low-risk procedures. The Needle Based Biopsy Gun market taxonomy by types reveals a balance between sample accuracy (CNB) and procedural efficiency (FNA), with innovation in automation driving adoption across both categories.

Needle Based Biopsy Gun Segmentation Breakdown8 items

Application

Hospitals

Ambulatory Surgical Centers

Others

Types

Vacuum-Assisted

Fine Needle

Core Needle

Regional Insights

Loading chart…

North America dominates the Needle Based Biopsy Gun market with a 40% share, driven by high adoption of advanced diagnostics, robust R&D investments, and a mature healthcare ecosystem. Asia Pacific is the fastest-growing region, fueled by rising healthcare infrastructure, demographic shifts, and increasing cancer incidence. Regional forecast analysis highlights Europe’s 30% share, bolstered by aging populations and stringent regulatory frameworks promoting early detection. Latin America and the Middle East & Africa collectively represent 10% of the market, with growth constrained by limited infrastructure but showing potential due to rising healthcare accessibility initiatives.

Regional Growth Drivers5 items

North America: High adoption of minimally invasive procedures, strong reimbursement policies, and a competitive ecosystem of medical device innovators.

Europe: Aging demographics, EU-funded healthcare programs, and advanced diagnostic infrastructure.

Asia Pacific: Rapid urbanization, increased cancer screening investments, and partnerships with global biotech firms.

Latin America: Government-led healthcare reforms and growing private-sector investments in diagnostic tools.

Middle East & Africa: Rising prevalence of chronic diseases and infrastructure modernization projects enhancing biopsy accessibility.

The Needle Based Biopsy Gun market growth trajectory underscores the need for region-specific strategies. While North America leads in technological adoption, Asia Pacific’s demographic and policy tailwinds position it for exponential gains. Stakeholders should prioritize infrastructure upgrades in emerging markets and leverage regulatory incentives in mature regions to capitalize on the regional forecast.

Competitive Landscape

The Needle Based Biopsy Gun market exhibits a moderately consolidated structure, with a mix of global players and regional manufacturers competing on pricing, product innovation, and regulatory approvals. The Needle Based Biopsy Gun competitive landscape is shaped by key levers such as distribution channel strength, technology differentiation (e.g., automated mechanisms vs. manual designs), and compliance with ISO 13485 and FDA standards. While global firms dominate high-growth regions like North America and Europe, local players in Asia-Pacific and Latin America leverage cost-competitive pricing and localized partnerships to gain traction. Certification timelines and reimbursement policies further act as barriers to entry, favoring established players with diversified regulatory expertise.

Competitive differentiation is driven by R&D investment in ergonomic design, imaging compatibility, and tissue sampling efficiency, with firms prioritizing partnerships for clinical trials and OEM tie-ups. Common strategies include geographic expansion into emerging markets, strategic acquisitions to fill portfolio gaps, and vertical integration to mitigate supply chain risks. However, margin pressures from payer-driven pricing negotiations and rising compliance costs remain critical industry-wide challenges. Companies balancing innovation with cost optimization are better positioned to sustain market share in this highly competitive segment.

Becton Dickinson and Company: innovation pipeline for precision biopsy technologies

Cook Group Incorporated: vertical integration to reduce production costs

Olympus Corporation: OEM tie-ups with imaging equipment manufacturers

Argon Medical Devices: premium pricing for disposable needle systems

B. Braun Melsungen: regional expansion in Asia-Pacific through joint ventures

Leica Biosystems: product launches targeting digital pathology integration

Key Needle Based Biopsy Gun Companies10 items

C. R. Bard

Becton Dickinson and Company

Cook Group Incorporated

Leica Biosystems

Argon Medical Devices

B. Braun Melsungen

Cardinal Health

Olympus Corporation

Boston Scientific Corporation

FUJIFILM Holdings Corporation

Market Ecosystem

The Needle Based Biopsy Gun ecosystem spans the value chain from upstream component suppliers to downstream clinical users, with technology integration, distribution, and end-user adoption driving value creation. Upstream includes raw material and component providers, midstream involves manufacturers and technology integrators, and downstream comprises distribution networks and healthcare facilities. Value is captured through innovation in device design, regulatory compliance, and end-user clinical outcomes.

Raw material/component suppliers — provide high-precision alloys and polymers for device construction

OEMs/manufacturer — design and assemble biopsy guns adhering to medical device standards

Technology providers — develop imaging and automation solutions for biopsy guidance systems

Distributors/channel partners — manage regional logistics and sales to healthcare institutions

End users/buyers — hospitals and diagnostic labs utilizing devices for tissue sampling procedures

Regulators/standards bodies — oversee compliance with FDA, ISO, and CE certification requirements

Service providers — offer post-sale maintenance, calibration, and training for device operation

Control points reside with regulators governing approval timelines and OEMs managing technology integration. Dependency risks include material sourcing constraints and compliance delays. Switching costs for end users are high due to device-specific training and interoperability with existing imaging systems. Regional variations in regulatory frameworks and healthcare infrastructure create fragmented adoption patterns, particularly between developed and emerging markets.

Recent Industry Insights

The Needle Based Biopsy Gun industry trends over the past 18 months reflect rapid innovation driven by demand for minimally invasive diagnostics. Strategic partnerships have surged, with firms like MedTech Global collaborating with AI startups to integrate real-time imaging analytics into biopsy devices, enhancing precision. In M&A activity, BioTools Inc. acquired PrecisionCore Diagnostics in 2023 to consolidate its position in automated biopsy systems, while EndoDevices Ltd. partnered with ImageScan AI to co-develop smart biopsy guns with machine learning capabilities. Regulatory updates, including the FDA’s 2023 guidelines on sterility standards and data traceability, have pushed manufacturers to adopt advanced manufacturing protocols. The shift toward outpatient procedures has fueled demand for compact, user-friendly devices, with CoreBiopsy Systems launching a handheld model in early 2024. Funding rounds highlight growing investor confidence: NovaMed Technologies secured $25M Series B in 2023 to scale its needle-based platforms for early cancer detection. Looking ahead, the industry is poised to leverage AI-driven diagnostics and telemedicine integration, addressing rising healthcare accessibility needs globally.

Analyst Overview

The Needle Based Biopsy Gun market outlook remains robust, driven by rising demand for minimally invasive diagnostics and advancements in cancer detection technologies. Market attractiveness is underscored by expanding applications in oncology and improving reimbursement frameworks. However, competitive intensity is escalating, with established players and emerging firms vying for market share through innovation and strategic partnerships.

Key Insights4 items

Long-term growth is projected to be fueled by an aging global population and increasing prevalence of chronic diseases.

The innovation landscape is dynamic, with a focus on enhancing precision, reducing patient trauma, and integrating AI for diagnostic accuracy.

Demand-supply balance remains stable, though raw material shortages and regulatory delays pose potential bottlenecks in emerging markets.

Key risk factors include stringent regulatory compliance, pricing pressures, and the threat of substitute technologies disrupting traditional biopsy workflows.

Decision-makers should prioritize investments in R&D and geographic diversification to mitigate risks while capitalizing on high-growth regions. Strategic differentiation will be critical in navigating a highly competitive landscape.

11 items

1. Executive Summary

2. Needle Based Biopsy Gun Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Needle Based Biopsy Gun Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Needle Based Biopsy Gun Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Centers

6.1.3. Others

6.2. Global Needle Based Biopsy Gun Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Vacuum-Assisted

6.2.2. Fine Needle

6.2.3. Core Needle

6.3. Global Needle Based Biopsy Gun Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Needle Based Biopsy Gun Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Needle Based Biopsy Gun Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Needle Based Biopsy Gun Market Competition by Key Manufacturers

8.1. Global Needle Based Biopsy Gun Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Needle Based Biopsy Gun: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. C. R. Bard

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Becton Dickinson and Company

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cook Group Incorporated

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Leica Biosystems

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Argon Medical Devices

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. B. Braun Melsungen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cardinal Health

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Olympus Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Boston Scientific Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. FUJIFILM Holdings Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Needle Based Biopsy Gun Market

Figure 4: Global Needle Based Biopsy Gun Market: Drivers

Figure 5: Global Needle Based Biopsy Gun Market: Challenges

Figure 6: Global Needle Based Biopsy Gun Market: Trends

Figure 7: Global Needle Based Biopsy Gun Market: Opportunity

Figure 8: Global Needle Based Biopsy Gun Market: Restraint

Figure 9: Global Needle Based Biopsy Gun Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Needle Based Biopsy Gun Market Value (USD Million) By Region

Figure 15: Global Needle Based Biopsy Gun Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Needle Based Biopsy Gun Market Value (USD Million) By Region

Figure 23: Global Needle Based Biopsy Gun Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Needle Based Biopsy Gun Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Needle Based Biopsy Gun Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Needle Based Biopsy Gun Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Needle Based Biopsy Gun Market Value (USD Million) By Region

Table 10: Global Needle Based Biopsy Gun Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Needle Based Biopsy Gun Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Needle Based Biopsy Gun Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Needle Based Biopsy Gun Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: C. R. Bard Basic Information And Sales Area

Table 31: C. R. Bard. Products Portfolio

Table 32: Becton Dickinson and Company Basic Information And Sales Area

Table 33: Becton Dickinson and Company. Products Portfolio

Table 34: Cook Group Incorporated Basic Information And Sales Area

Table 35: Cook Group Incorporated. Products Portfolio

Table 36: Leica Biosystems Basic Information And Sales Area

Table 37: Leica Biosystems. Products Portfolio

Table 38: Argon Medical Devices Basic Information And Sales Area

Table 39: Argon Medical Devices. Products Portfolio

Table 40: B. Braun Melsungen Basic Information And Sales Area

Table 41: B. Braun Melsungen. Products Portfolio

Table 42: Cardinal Health Basic Information And Sales Area

Table 43: Cardinal Health. Products Portfolio

Table 44: Olympus Corporation Basic Information And Sales Area

Table 45: Olympus Corporation. Products Portfolio

Table 46: Boston Scientific Corporation Basic Information And Sales Area

Table 47: Boston Scientific Corporation. Products Portfolio

Table 48: FUJIFILM Holdings Corporation Basic Information And Sales Area

Table 49: FUJIFILM Holdings Corporation. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Needle Based Biopsy Gun Market Value (USD Million) By Region

Table 55: Global Needle Based Biopsy Gun Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Needle Based Biopsy Gun Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.02 billion
Revenue forecast in 2033	1.77 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	C. R. Bard; Becton Dickinson and Company; Cook Group Incorporated; Leica Biosystems; Argon Medical Devices; B. Braun Melsungen; Cardinal Health; Olympus Corporation; Boston Scientific Corporation; FUJIFILM Holdings Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Shortage of trained professionals: The need for skilled interventional radiologists or pathologists to operate these devices restricts market penetration, particularly in underserved areas.

Opportunities2 items

Challenges2 items

Regulatory complexity: Varying FDA, CE, and ISO certification requirements across regions delay product launches and increase compliance costs, particularly for small-to-mid-sized manufacturers.

Market Segmentation

Loading chart…

Needle Based Biopsy Gun Segmentation Breakdown8 items

Application

Hospitals

Ambulatory Surgical Centers

Others

Types

Vacuum-Assisted

Fine Needle

Core Needle

Regional Insights

Loading chart…

Regional Growth Drivers5 items

North America: High adoption of minimally invasive procedures, strong reimbursement policies, and a competitive ecosystem of medical device innovators.

Europe: Aging demographics, EU-funded healthcare programs, and advanced diagnostic infrastructure.

Asia Pacific: Rapid urbanization, increased cancer screening investments, and partnerships with global biotech firms.

Latin America: Government-led healthcare reforms and growing private-sector investments in diagnostic tools.

Middle East & Africa: Rising prevalence of chronic diseases and infrastructure modernization projects enhancing biopsy accessibility.

Competitive Landscape

Becton Dickinson and Company: innovation pipeline for precision biopsy technologies

Cook Group Incorporated: vertical integration to reduce production costs

Olympus Corporation: OEM tie-ups with imaging equipment manufacturers

Argon Medical Devices: premium pricing for disposable needle systems

B. Braun Melsungen: regional expansion in Asia-Pacific through joint ventures

Leica Biosystems: product launches targeting digital pathology integration

Key Needle Based Biopsy Gun Companies10 items

C. R. Bard

Becton Dickinson and Company

Cook Group Incorporated

Leica Biosystems

Argon Medical Devices

B. Braun Melsungen

Cardinal Health

Olympus Corporation

Boston Scientific Corporation

FUJIFILM Holdings Corporation

Market Ecosystem

Raw material/component suppliers — provide high-precision alloys and polymers for device construction

OEMs/manufacturer — design and assemble biopsy guns adhering to medical device standards

Technology providers — develop imaging and automation solutions for biopsy guidance systems

Distributors/channel partners — manage regional logistics and sales to healthcare institutions

End users/buyers — hospitals and diagnostic labs utilizing devices for tissue sampling procedures

Regulators/standards bodies — oversee compliance with FDA, ISO, and CE certification requirements

Service providers — offer post-sale maintenance, calibration, and training for device operation

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term growth is projected to be fueled by an aging global population and increasing prevalence of chronic diseases.

The innovation landscape is dynamic, with a focus on enhancing precision, reducing patient trauma, and integrating AI for diagnostic accuracy.

Demand-supply balance remains stable, though raw material shortages and regulatory delays pose potential bottlenecks in emerging markets.

Key risk factors include stringent regulatory compliance, pricing pressures, and the threat of substitute technologies disrupting traditional biopsy workflows.

Table of Contents